Geert Cauwenbergh joins RXi as CEO
This article was originally published in Scrip
RNAi focused biotech, RXi Pharmaceuticals, has appointed Dr Geert Cauwenbergh president and CEO and a member of the board of directors. Dr Cauwenbergh was most recently chair and CEO of Barrier Therapeutics.
You may also be interested in...
Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.